SCD-1, a key rate-limiting enzyme in FFA desaturation, is significantly elevated in the liver of obese mice on high-fat diets [6], and it is a potential therapeutic target for obesity, diabetes, and other metabolic diseases, including NAFLD [6, 38]. Here, SCD is linked to metabolic dysfunction-associated steatotic liver disease.